Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings guidance for the year. The stock has been trading at a high valuation ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00. The company’s shares closed yesterday at $846.83.

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images) Eli Lilly stock (NYSE: LLY ...

JPMorgan analyst Chris Schott views the post-earnings weakness in Eli Lilly (LLY) shares as a buying opportunity. While the results missed expectations, mostly on wholesaler destocking for ...